LyphoMed licenses ophthalmic drug
Executive Summary
Generic manufacturer signs a development and marketing agreement with pediatric ophthalmologist Helen Hittner, MD, covering dl-Selenomethionine for treatment of retinopathy in premature infants. An IND has been approved by FDA. The agreement is LyphoMed's third covering a brandname Rx drug: the company currently markets Pentam (pentamidine) and has a development and worldwide marketing agreement covering Medco Research's Adenocard (adenosine).